|

Abiraterone Acetate Clinical Trials

20 actively recruiting trials across 16 locations

▲ +2 trials since June 2026

Also known as: 154229-18-2, Abiraterone, Androsta-5, BR9004, BR9004-1 +11 more

Pipeline

Phase 2: 14Phase 3: 4Phase 1/2: 1

Top Sponsors

  • Merck Sharp & Dohme LLC2
  • Astellas Pharma Global Development, Inc.2
  • VA Office of Research and Development1
  • University of Washington1
  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1

Indications

  • Cancer20
  • Prostate Cancer4
  • Stage IVA Prostate Cancer AJCC v83
  • Metastatic Hormone-sensitive Prostate Cancer2
  • Stage III Prostate Cancer AJCC v82

Other3 trials

A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Phase 1/2
Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer
Phase 2
Phase II Randomised Controlled Trial of Patient-specific Adaptive vs. Continuous Abiraterone or eNZalutamide in mCRPC
Phase 2

Houston, Texas2 trials

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M D Anderson Cancer Center

Phase 2
Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

Ben Taub General Hospital

Phase 2

Birmingham, Alabama1 trial

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

University of Alabama at Birmingham Cancer Center

Phase 2

Huntsville, Alabama1 trial

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Clearview Cancer Institute

Phase 2

Anchorage, Alaska1 trial

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

Site US10052

Phase 2

Goodyear, Arizona1 trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

City of Hope Cancer Center Phoenix

Phase 3

Scottsdale, Arizona1 trial

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic in Arizona

Phase 2

Tucson, Arizona1 trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

The University of Arizona Cancer Center - North Campus ( Site 0073)

Phase 3

Duarte, California1 trial

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer

City of Hope Medical Center

Phase 2

Los Angeles, California1 trial

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

VA Greater Los Angeles Healthcare System

Phase 2

Orange, California1 trial

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040)

Phase 3

San Francisco, California1 trial

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone

University of California, San Francisco

Phase 2

West Los Angeles, California1 trial

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Phase 2

Atlanta, Georgia1 trial

REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial

Emory Proton Therapy Center

Phase 3

Baltimore, Maryland1 trial

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2

Cleveland, Ohio1 trial

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company

Pittsburgh, Pennsylvania1 trial

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

University of Pittsburgh Cancer Institute (UPCI)

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.